Adipose Natural Killer Cells and Metabolic Homeostasis: Mechanisms, Clinical Relevance, and Therapeutic Implications

Abstract

Adipose tissue has emerged as a dynamic immunometabolic organ, with resident immune cell populations such as natural killer (NK) cells playing pivotal roles in metabolic homeostasis. Recent advances in immunometabolism have elucidated the bidirectional relationship between adipose NK cells and metabolic health, particularly in the context of obesity, insulin resistance, and type 2 diabetes. This review synthesizes current evidence on the epidemiology, pathophysiology, clinical features, diagnostic approaches, management strategies, and guideline recommendations concerning adipose NK cells, with a focus on their mechanistic roles in metabolic regulation and potential as therapeutic targets.

Introduction

Metabolic homeostasis relies on a complex interplay between nutrient sensing, hormonal signaling, and immune cell function within adipose tissue. While macrophages and T cells have been extensively studied in this context, natural killer (NK) cells have recently gained attention for their capacity to modulate both local and systemic metabolic processes. NK cells, traditionally recognized for their cytotoxicity against virally infected or transformed cells, are now acknowledged as regulators of inflammation and adipocyte function within adipose depots. Their dysregulation has been implicated in metabolic disorders, highlighting the need for clinicians and researchers to understand their biology and clinical impact.

Epidemiology / Disease Burden

Obesity and its associated metabolic sequelae, such as insulin resistance and type 2 diabetes, represent global health challenges with escalating prevalence. Epidemiological studies indicate a correlation between metabolic syndrome and altered immune cell profiles within adipose tissue, including increased NK cell infiltration. Population-based research demonstrates that individuals with higher adiposity exhibit both quantitative and qualitative changes in adipose-resident immune cells, suggesting a role for immune dysregulation in the pathogenesis of metabolic disease. The burden is particularly pronounced in populations with high rates of obesity and metabolic syndrome, underlining the clinical relevance of immune-metabolic interactions.

Pathophysiology

Adipose NK cells constitute a distinct subset with unique phenotypic and functional properties compared to their circulating counterparts. In lean states, NK cells contribute to tissue homeostasis, but in obesity, their numbers and activation status are elevated, promoting a pro-inflammatory environment. Mechanistically, adipose NK cells secrete interferon-gamma (IFN-γ), which activates pro-inflammatory M1 macrophages and impairs insulin signaling. Crosstalk between adipocytes and NK cells, mediated by cytokines and adipokines such as leptin and IL-15, further amplifies inflammation. This chronic low-grade inflammation disrupts insulin sensitivity and promotes metabolic derangements. Recent mouse models have demonstrated that NK cell depletion can ameliorate insulin resistance and improve glucose tolerance, underscoring their pathogenic contribution.

Risk Factors

Risk factors for dysregulated adipose NK cell activity include obesity, sedentary lifestyle, high-fat diet, and genetic predisposition. Age, sex, and comorbidities such as non-alcoholic fatty liver disease and cardiovascular disease can also modulate NK cell function and contribute to a pro-inflammatory adipose microenvironment. Additionally, factors influencing adipose tissue remodeling, such as hypoxia and oxidative stress, may alter NK cell recruitment and activation, exacerbating metabolic dysfunction.

Clinical Features

Although dysregulated adipose NK cell activity is not directly discernible clinically, it underlies the pathogenesis of metabolic syndrome manifestations, including central obesity, impaired glucose tolerance, dyslipidemia, and hypertension. Patients may present with signs and symptoms attributable to insulin resistance and chronic inflammation, such as acanthosis nigricans, hepatomegaly, and increased cardiovascular risk. Subclinical inflammation associated with altered NK cell activity is often reflected in elevated circulating inflammatory markers, which are linked to adverse metabolic outcomes.

Diagnosis

Currently, there are no routine clinical assays for assessing adipose NK cell function in patients. Research protocols often employ flow cytometry to quantify NK cell subsets in adipose tissue biopsies, with surface markers such as CD56, CD16, and NKp46. Functional assays measuring cytokine production, degranulation, and cytotoxicity are used in experimental settings. Indirectly, metabolic syndrome is diagnosed based on clinical and laboratory criteria, and emerging biomarkers such as circulating IFN-γ, adipokines, and inflammatory mediators may reflect underlying immune dysregulation.

Treatment & Management

Management of metabolic disease linked to adipose NK cell dysregulation primarily involves lifestyle modification diet, exercise, weight loss and pharmacological interventions targeting insulin resistance and inflammation. No approved therapies specifically modulate adipose NK cell function in clinical practice, but anti-inflammatory agents, such as thiazolidinediones and statins, may exert pleiotropic effects on immune-metabolic pathways. Bariatric surgery has been shown to reduce adipose inflammation and may indirectly modulate NK cell activity. Ongoing research aims to identify novel agents that can selectively target pathogenic NK cell subsets without compromising host defense.

Recent Advances / Emerging Therapies

Recent advances in single-cell transcriptomics and high-dimensional flow cytometry have unraveled the heterogeneity of adipose NK cells and their dynamic interplay with other immune cells. Preclinical models highlight the therapeutic potential of targeting cytokine signaling (e.g., IL-15 blockade) and metabolic checkpoints (e.g., mTOR inhibition) to modulate NK cell activity. Experimental therapies, such as adoptive NK cell transfer and immune checkpoint inhibitors, are being explored in oncologic and metabolic contexts. Furthermore, microbiome-targeted interventions may indirectly influence adipose NK cell function by modulating systemic inflammation.

Guideline Recommendations

Current clinical guidelines for obesity and metabolic syndrome emphasize risk factor modification and metabolic control but do not specifically address immune cell modulation. However, professional societies recognize the importance of inflammation in metabolic disease pathogenesis and advocate for research into novel immunometabolic targets. Clinicians should remain apprised of emerging evidence and consider immune-metabolic interactions when managing patients with complex metabolic phenotypes.

Conclusion

Adipose natural killer cells are integral to the regulation of metabolic homeostasis and represent promising targets for therapeutic intervention in obesity-related metabolic disorders. A growing body of evidence implicates dysregulated NK cell activity in the pathogenesis of insulin resistance and type 2 diabetes, mediated by chronic adipose inflammation. While clinical translation remains in its infancy, advancements in immunometabolism and targeted therapies hold promise for mitigating disease burden. Ongoing research and interdisciplinary collaboration will be essential in harnessing the full potential of adipose NK cells for improving metabolic health outcomes in at-risk populations.